Onco360 to distribute Gilead Sciences’ Zydelig

Onco360 recently announced that it has been selected to be part of the limited network to distribute Gilead Sciences’ Zydelig (idelalisib) tablets.

Onco360 is one of the nation’s fastest-growing independent Oncology Pharmacy and Clinical Support Services companies.

It will now be part of the highly limited Specialty Pharmacy network of Zydelig tablets, which has just received approval by the US Food and Drug Administration (FDA) for three different types of blood cancers.

The agency has approved the drug for three different B-cell blood cancers, including patients with relapsed chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL) and with small lymphocytic lymphoma (SLL). According to Onco360, the drug is immediately available for order through Onco360 and its network of OncoMed Pharmacies.

As a limited distribution supplier, Onco360 assists pharmaceutical partners broaden the reach and access of their products, but in a tightly controlled and efficient manner.

PharMerica Corporation, a leading institutional pharmacy, specialty infusion and hospital services company acquired a significant minority stake of Onco360. Under the terms of the agreement, PharMerica has the option to acquire the portion of Onco360 it does not already own over the next several years.

Limited Distribution Network Report Available